Boehringer Ingelheim Limited Archives | Page 3 of 3

Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches

Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. [...]

Boehringer provides update on iclepertin Phase III program in schizophrenia

Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were not met.1–6 Overall, no statistically significant effects on cognition or functioning were observed in patients treated with iclepertin versus placebo at six months.1 All three trials demonstrated that iclepertin, a [...]